BHV-1310
/ Biohaven
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 03, 2025
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
(PRNewswire)
- "IgG MoDE Degraders (1300/1310): BHV-1300 Phase 1 with the optimized subcutaneous formulation completing in 1H 2025. BHV-1310 completion of preclinical testing prior to anticipated FIH study initiating 1H 2025...Phase 1 with BHV-1400 and BHV-1600 expected to be completed in 1H 2025...Kv7 Activator (BHV-7000): Pivotal major depressive disorder topline results expected in 2H 2025. Focal epilepsy study topline results expected in 1H 2026."
Clinical data • Preclinical • Trial completion date • Epilepsy • IgA Nephropathy • Immunology • Major Depressive Disorder
1 to 1
Of
1
Go to page
1